ALNYLAM PHARMACEUTICALS, INC.

Form 4

December 22, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSI							OMB APPROVAL			
	Washington, D.C. 20549						N OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL O SECURITIES Filed pursuant to Section 16(a) of the Securities Exchaution 16(b).						burden hours per response nange Act of 1934, cct of 1935 or Section				
Print or Type	Responses)									
	Address of Reporting I-Alexandre C	Sym AL PH	2. Issuer Name and Ticker or Trading Symbol ALNYLAM PHARMACEUTICALS, INC. [ALNY]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 300 THIRD STREET			3. Date of Earliest Transaction (Month/Day/Year) 12/18/2015			X Officer (give title Other (specify below) SVP, Chief Business Officer				
CAMBRID	(Street) OGE, MA 02142		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(State)	(Zip)				Person				
(City)	(State)	(Zip)				Acquired, Disposed	of, or Beneficia	ally Owned		
.Title of Security Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye	Code ar) (Instr. 8)	4. SecurionAcquirect Disposed (Instr. 3,	(A) or d of (D) 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		- f l l			(D) Price					
æminder: Rej	port on a separate line	e for each class of	securities ben	Perso infor requi	ons who res mation con ired to resp ays a curre	or indirectly. spond to the colletained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	Ι

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		•		Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		(
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	ļ
Stock Option (right to buy)	\$ 88.95	12/18/2015		A	15,012		<u>(1)</u>	12/18/2025	Common Stock	15,012	

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Gros David-Alexandre C 300 THIRD STREET CAMBRIDGE, MA 02142

SVP, Chief Business Officer

Signatures

By: /s/ Michael P. Mason, Attorney-In-Fact For: David-Alexandre C.

Gros 12/22/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2